1276 related articles for article (PubMed ID: 30603725)
1. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
Liu X; Qin S
Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
[TBL] [Abstract][Full Text] [Related]
3. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
4. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.
Biglow L; Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():22. PubMed ID: 34917675
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.
Nishida N; Kudo M
Hepatol Res; 2018 Jul; 48(8):622-634. PubMed ID: 29734514
[TBL] [Abstract][Full Text] [Related]
13. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].
Xiao ZL; Wang P; Lei LP; Zhou HB; Hu HP
Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):732-736. PubMed ID: 31594104
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Immunotherapy for Hepatocellular Carcinoma.
Nakano S; Eso Y; Okada H; Takai A; Takahashi K; Seno H
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218257
[TBL] [Abstract][Full Text] [Related]
16. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
17. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma.
Yang J; Eresen A; Scotti A; Cai K; Zhang Z
Am J Cancer Res; 2021; 11(2):337-349. PubMed ID: 33575075
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in immunotherapy for hepatocellular carcinoma.
Khan AA; Liu ZK; Xu X
Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
[TBL] [Abstract][Full Text] [Related]
19. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
Donne R; Lujambio A
Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
[TBL] [Abstract][Full Text] [Related]
20. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice.
Giannini EG; Aglitti A; Borzio M; Gambato M; Guarino M; Iavarone M; Lai Q; Levi Sandri GB; Melandro F; Morisco F; Ponziani FR; Rendina M; Russo FP; Sacco R; Viganò M; Vitale A; Trevisani F;
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]